These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21747367)

  • 1. Gates eyes biotechs as for-profit investments.
    Orelli B
    Nat Biotechnol; 2011 Jul; 29(7):559. PubMed ID: 21747367
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotechs for pennies?
    Jacobs T
    Nat Biotechnol; 2004 Dec; 22(12):1509. PubMed ID: 15583652
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 4. Cash-strapped biotechs find financing alternative.
    Mitchell P
    Nat Biotechnol; 2004 Sep; 22(9):1057-8. PubMed ID: 15340452
    [No Abstract]   [Full Text] [Related]  

  • 5. Chinese biotechs wrestle with transparency, cultural hurdles.
    Jia H; Tang F; Orelli B
    Nat Biotechnol; 2011 May; 29(5):377-8. PubMed ID: 21552225
    [No Abstract]   [Full Text] [Related]  

  • 6. Russian fund steps up investments in innovative biotechs.
    Katsnelson A
    Nat Biotechnol; 2012 Jan; 30(1):9-11. PubMed ID: 22231078
    [No Abstract]   [Full Text] [Related]  

  • 7. European markets target foreign biotechs.
    Louët S
    Nat Biotechnol; 2003 Jul; 21(7):719. PubMed ID: 12833075
    [No Abstract]   [Full Text] [Related]  

  • 8. Why these biotechs are as hot as net stocks. Wall Street's betting big on a genetic technology that burned it badly before. Monoclonal antibodies still don't cure cancer--but this time they may actually pay off.
    McLean B
    Fortune; 2000 Jan; 141(1):132-4, 135. PubMed ID: 10788044
    [No Abstract]   [Full Text] [Related]  

  • 9. Foundation's funding.
    Kowalski HE
    Nature; 2002 May; 417(6887):379. PubMed ID: 12024190
    [No Abstract]   [Full Text] [Related]  

  • 10. Korean biotechs seize opportunity to list on public markets.
    Louët S
    Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotechs feel the pain.
    Ledford H
    Nature; 2009 Jan; 457(7226):136-7. PubMed ID: 19129814
    [No Abstract]   [Full Text] [Related]  

  • 12. Shift toward early-stage deals favors biotechs.
    Lawrence S
    Nat Biotechnol; 2006 Jan; 24(1):6. PubMed ID: 16404377
    [No Abstract]   [Full Text] [Related]  

  • 13. Hedge funds gain edge by doubling biotech investments.
    Ransom J
    Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
    [No Abstract]   [Full Text] [Related]  

  • 14. Maturing biotechs turn to pharma's markets.
    Ratner M
    Nat Biotechnol; 2005 Mar; 23(3):269. PubMed ID: 15765067
    [No Abstract]   [Full Text] [Related]  

  • 15. US venture capital for biotechnology.
    Dibner MD; Trull M; Howell M
    Nat Biotechnol; 2003 Jun; 21(6):613-7. PubMed ID: 12776144
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotechs await single European financial market.
    Louët S
    Nat Biotechnol; 2003 Dec; 21(12):1417. PubMed ID: 14647312
    [No Abstract]   [Full Text] [Related]  

  • 17. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 18. Coming to terms.
    Oden DH; Wolfson JA; Marshall CW
    Nat Biotechnol; 2010 Feb; 28(2):120-2. PubMed ID: 20139940
    [No Abstract]   [Full Text] [Related]  

  • 19. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 20. Falling stock prices put the squeeze on biotech start-ups.
    Lehrman S
    Nature; 1995 Jan; 373(6511):178. PubMed ID: 7816117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.